Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months [...]

Continue reading " Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results "

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided an update to the preliminary revenue and adjusted earnings per share growth rate guidance provided to investors at the Company’s recent analyst R&D day meeting on December 3, 2009. The Company now believes that the 2010 overall revenue percentage growth rate will be in the mid-teens and re-affirms that [...]

Continue reading " OSI Pharmaceuticals Updates Preliminary Revenue & Re-affirms Adjusted Earnings Growth Rate Guidance for 2010 "

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) reported unaudited financial results for the three and twelve months ended September 30, 2009.
For the fourth quarter of fiscal 2009, AVANIR reported a net loss from continuing operations of $7.0 million, or $0.09 per share, compared with a net loss from continuing operations of $5.2 million, or $0.07 per share, for [...]

Continue reading " AVANIR Pharmaceuticals Announces Fiscal 2009 Fourth Quarter and Full Year Financial Results "

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that it will release unaudited financial results for the quarter and fiscal year ended September 30, 2009 before market open on Tuesday, November 24, 2009. Keith Katkin, President and Chief Executive Officer, Randall Kaye, M.D., Senior Vice President and Chief Medical Officer, and Christine Ocampo, Vice President, Finance, will [...]

Continue reading " AVANIR Pharmaceuticals Invites Investors to Fourth Quarter and Fiscal Year End Conference Call "

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), reported its financial results for the quarter ended September 30, 2009.

Related posts

AVANIR Pharmaceuticals Announces Fiscal 2010 First Quarter Financial Results (0)
Medical Properties Trust, Inc. Reports Fourth Quarter and Full-Year 2009 Results (0)
Array BioPharma to [...]

Continue reading " RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2009 "

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced financial and operating results for the third quarter ended September 30, 2009.
Total product revenue was $65.7 million for the third quarter of 2009, a 53 percent increase compared to $42.9 million for the third quarter of 2008. Total product revenue for the first nine months of 2009 was $162.7 million [...]

Continue reading " Salix Pharmaceuticals Reports 3Q2009 Results "

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced its third quarter 2009 financial results.
BioSante incurred a net loss of approximately $6.4 million or ($0.21) per share for the quarter ended September 30, 2009, compared to a net loss of $6.6 million or ($0.24) per share for the same period in 2008. This decrease in net loss was [...]

Continue reading " BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results "

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.

Related posts

NovaMed Announces Fourth Quarter 2009 Conference Call (0)
IASIS Healthcare to Broadcast Its Fiscal First Quarter 2010 Conference Call Live on [...]

Continue reading " 04:15 PM Eastern Daylight Time Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast "

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided an update on the progress of two early clinical programs from its diabetes and obesity R&D operations. Phase I clinical trial data on both PSN821 and PSN602 showed positive evidence of clinical activity, and both candidates are now progressing to the next stage of clinical development.

Related posts

Array BioPharma [...]

Continue reading " OSI Pharmaceuticals Provides Update on Diabetes and Obesity Clinical Programs "